Who we serve
Seven customer segments, with a primary focus on R&D-intensive operators.
The same foundation, the same compliance shell, a different lens on the lifecycle. Primary: pharma, biotech, CRO and CDMO. Adjacent: medtech. Secondary: hospitals and payers.
Primary segment · Pharma
Collapse the AI vendor stack. Ship 9–18 months faster.
Trial-sponsor scale, from molecule to market: one platform across protocol, evidence, regulatory and access.
- GenoDev
- GenoRWE
- GenoAccess
What they do on day one
- ICH M11 protocol authoring (Phase I–III) with auto-cited safety and efficacy rationale
- Patient stratification and adaptive site selection using EHR, claims and registry triangulation
- Federated cohort assembly across 80+ datasets (OMOP CDM, SDTM/ADaM, AACT)
- Label expansion and post-market RWE on the same tenant as your development work
- HEOR and global value-dossier first drafts across 12+ markets in parallel
- Regulatory dossier autopack: FDA, EMA, CDSCO and PMDA cross-jurisdiction filings
- Companion-diagnostic strategy linked to biomarker and genomic experts
Qualitative value
- Replace 8–12 point AI vendors with one platform and a single audit surface
- Diverse-population evidence: 120K+ Indian and African oncology records built in
- Compliance pre-cleared (GxP, 21 CFR Part 11, EU AI Act): IT review in weeks, not quarters
- Cross-functional handoffs eliminated: development, RWE and HEOR share one data spine
- 30–40%shorter Phase II setup
- $8–15Msaved per Phase II asset
- 60%faster value-dossier first draft
Sources: Tufts CSDD ($2.6B); McKinsey ($60–110B GenAI value); Genovant design-partner pilots.
Primary segment · Biotech
Build a pharma-grade partnering package on Series-B capital.
A capital-efficient path to a partnering moment. Pull your out-licensing window in by 9–18 months, at a higher valuation.
- GenoDev
- GenoRWE
- GenoAccess
What they do on day one
- Lead-asset Phase 2 inflection package: integrated trial design, RWE and access story
- Pharma-grade out-licensing dossier auto-built from your evidence base
- Capital-efficient trial designs (single-arm, basket, platform) modelled in silico first
- Companion diagnostic and biomarker strategy linked to molecular and genomic experts
- Rare-disease prevalence engine for orphan and ultra-orphan asset positioning
- Indication selection: prioritise therapy areas by RWE-informed addressable population and access path
Qualitative value
- Pharma BD questions answered in days, not months of consultant-led builds
- Avoid hiring a 20-person internal data team
- Out-license at a higher valuation with an evidence and access narrative beyond the Phase 2 readout
- Diverse-population evidence supports ex-US partnering and emerging-market value
- 30–50%capital efficiency to Phase 2 inflection
- 9–18 moearlier partnering or out-licence
- 3×more therapy-area packages per FTE
Sources: Genovant pilot conversations; analogous Series-B to BD-deal benchmarks (BioCentury, PitchBook).
Primary segment · CRO
Win bids competitors can’t quote on. Lift win rates 20–30%.
The global CRO market reaches roughly $93–100B in 2026. Differentiate sponsor bids with named sites, modelled enrolment and risk-priced timelines.
- GenoDev
- GenoRWE
What they do on day one
- Site feasibility scoring at scale: 240+ sites in one run with EHR and claims signals
- Adaptive trial design and enrolment simulation across multiple comparators
- EHR and claims-driven patient recruitment that surfaces unconventional high enrollers
- Sponsor-bid analytics and differentiated proposals with named sites and modelled timeline ranges
- Country-mix optimisation: emerging-market sites with regulatory-cleared paths
- Risk-priced timelines: enrolment-curve forecasting with confidence intervals
Qualitative value
- Bid with a consulting-grade proposal while competitors send a one-pager and a price
- Diverse-population sites available out of the box: India, Africa and LatAm depth
- Margin protection: less rework and fewer protocol amendments through in-silico pre-testing
- Sponsor stickiness: one platform from Phase I to IV, with Phase 4 RWE on the same tenant
- 2–3×more accurate site feasibility scoring
- 8×faster federated cohort assembly
- 20–30%win-rate uplift on sponsor bids
Sources: MarketsandMarkets ($93B CRO market 2026); Mordor Intelligence ($93B, 8.3% CAGR); Genovant CRO design-partner pilots.
Primary segment · CDMO
Predict deviations before the batch starts. Cut CMC drafting 40%.
The global CDMO market reaches roughly $220–275B in 2026. The next decade is won by CDMOs that turn MES and LIMS data into AI-grade process intelligence.
- GenoDev
- GenoAccess
What they do on day one
- Process analytics and deviation prediction (PAT) from continuous MES and LIMS signals
- CMC section auto-drafting for IND, NDA, BLA and ex-US filings
- Tech-transfer dossier generation with site-to-site comparability auto-built
- Supply-chain risk monitoring across API, excipient and packaging tiers
- Comparability assessments and post-approval change packages
- Stability data review and trend analysis for cGMP-validated lots
Qualitative value
- Win complex modality work: GLP-1 peptides, HPAPI, ATMPs, sterile injectables
- Sponsor-facing transparency dashboards on batch status, deviations and predicted yield
- Embedded compliance: a 21 CFR Part 11 audit trail on every PAT alert and CMC draft
- Free up senior CMC scientists: the model drafts, they review and sign
- 40%less time drafting CMC sections
- 25–35%earlier deviation prediction (PAT)
- 70%of tech-transfer dossier auto-generated
Sources: Fortune Business Insights ($273B CDMO 2026); Precedence Research ($211B 2026); Genovant CDMO pilots.
Adjacent segment · Medtech & devices
Global access in one build, not country by country.
Combination-product complexity is rising: devices, drugs and software all need RWE, post-market evidence and global HTA packs. Genovant runs them on one platform.
- GenoDev
- GenoRWE
- GenoAccess
What they do on day one
- Companion-diagnostic development support: biomarker, validation and CDx panel
- Post-market RWE for 510(k), PMA, PMS and EU MDR/IVDR post-market obligations
- Real-world clinical performance studies for FDA, EMA and NMPA submissions
- Reimbursement and HTA dossier generation for 12+ markets in parallel
- Adverse-event signal detection across MAUDE, EUDAMED and Yellow Card
- Connected-device data ingestion: wearables, implantables and continuous monitors
Qualitative value
- Medtech regulatory complexity (MDR/IVDR, IDE, post-market) handled in one platform
- Faster ex-US launches: HEOR, HTA and the payer story built in parallel, not in sequence
- SaMD-friendly: ready for AI/ML predetermined change control
- Health-economics narratives for value-based contracts with payers and IDNs
- 50%faster post-market RWE study completion
- 3–4×more payer and reimbursement scenarios modelled
- 12+markets covered with one HEOR/HTA build
Sources: FDA MAUDE annual reports; EU MDR/IVDR implementation tracker; Genovant medtech design-partner conversations.
Secondary segment · Hospitals
Decision support that pays for itself in trial recruitment.
Hospitals sit on the most clinically rich data in healthcare. Genovant turns it into bedside decision support and a recurring revenue stream.
- GenoRWE
- GenoAccess
- GenoDev (sponsor-side)
What they do on day one
- Clinical decision support at the point of care: oncology, rare disease, cardiometabolic
- Trial-recruitment uplift: 30–50% lower recruitment cost as a preferred pharma site
- Population-health analytics across attributed lives and value-based-care contracts
- Quality-measure reporting (HEDIS, MIPS, AHRQ) with an auto-cited evidence chain
- Specialty-pharmacy adherence and outcomes tracking for high-cost therapies
- Tumour-board and MDT decision-support augmentation with multimodal RAG
Qualitative value
- Preferred-site status with top-10 pharma sponsors: a pipeline of trial revenue
- Hospital data stays in your perimeter: federated reads, never raw extraction
- Clinician-trust UX: every recommendation is cited and traceable to source
- A health-equity narrative for board and community: diverse-population validated models
- 30–50%lower trial-recruitment cost
- 2–4×more pharma co-development deals
- $1–5Madditional pharma-trial revenue per year
Sources: SCRS Site Sustainability Report; Tufts CSDD site-cost benchmarks; Genovant hospital partner conversations.
Secondary segment · Payers & insurers
Outcomes-based contracts you can actually adjudicate.
Risk-adjustment lift, outcomes-based contract design and prior-auth precision, all from the platform pharma uses to design the trial.
- GenoRWE
- GenoAccess
What they do on day one
- Risk-adjustment model uplift across MA, ACA, Medicaid and commercial books
- Outcomes-based contract design and adjudication with pharma sponsors
- Inappropriate prior-auth reduction through clinical-evidence-grounded utilisation
- Population-health analytics with an SDOH overlay for community-targeted interventions
- Specialty-drug formulary policy with HEOR cost-effectiveness models
- Real-world coverage with evidence development (CED) for novel therapies
Qualitative value
- A symmetric data position with pharma: adjudicate contracts without information asymmetry
- Member-level outcomes attribution across care settings via OMOP CDM mapping
- Compliance pre-cleared for HIPAA, state privacy laws (CMIA, CCPA) and 42 CFR Part 2
- A cleaner formulary policy story for regulators and employer groups
- 20–30%lift in risk-adjustment accuracy
- $1–5Moutcomes-based contract revenue per year
- 15–25%reduction in inappropriate PA approvals
Sources: AHIP outcomes-based contracting study; Avalere RWE-OBC framework; Genovant payer design-partner conversations.
Quantified portfolio ROI
What a multi-segment customer realises in years 1–3.
Conservatively modelled: mid-range from internal pilots and benchmarks against best-in-class point tools. Value compounds as additional teams onboard onto the same foundation, with no re-integration cost.
| Segment | Efficiency gain | Financial impact | Strategic outcome |
|---|---|---|---|
| Pharma | 30–40% Phase II setup | $8–15M saved per asset | 60% faster dossiers |
| Biotech | 30–50% capital efficiency | 9–18 mo earlier BD | 3× TA packages per FTE |
| CRO | 2–3× feasibility accuracy | 8× cohort assembly | 20–30% win-rate uplift |
| CDMO | 40% CMC drafting time | 25–35% earlier PAT alerts | 70% tech-transfer auto-generated |
| Medtech | 50% faster post-market RWE | 3–4× HEOR scenarios | 12+ markets in one build |
| Hospital | 30–50% trial recruitment cost | 2–4× co-development deals | $1–5M trial revenue per year |
| Payer | 20–30% risk-adjustment accuracy | $1–5M OBC revenue per year | 15–25% PA precision |
Compounds with every new team onboarded: the same foundation, the same compliance shell, no re-integration cost.